Novo Nordisk Strikes Back: Pill Prescriptions Top 3 Million as FDA and Pipeline Add Firepower
Veröffentlicht: 27.06.2026 um 10:07 Uhr, Redaktion boerse-global.de
The narrative around Novo Nordisk is shifting decisively. After months of investor skepticism, the Danish pharma giant has unleashed a cascade of positive catalysts that lifted shares more than 8% over the past week, closing Friday at €42.19 — a near-40% recovery from its March trough. The rally is not just a bounce; it reflects genuine operational momentum and strategic wins.
Central to the resurgence is the runaway success of oral Wegovy. Since its US launch in January 2026, physicians have written over three million prescriptions for the pill, underscoring a clear patient preference for tablets over injections. That adoption curve got a powerful tailwind from the FDA last week: the agency moved to remove semaglutide from its 503B compounding list, effectively barring unauthorized pharmacies from mixing copycat versions. The move hands Novo Nordisk exclusive market protection for both Ozempic and Wegovy, strengthening its pricing power and volume trajectory.
Europe is also joining the story. France became the first EU country to announce reimbursement for obesity drugs including Wegovy — a policy shift that analysts expect other member states to follow. Meanwhile, a broader rotation out of tech stocks into healthcare has lifted the XLV sector index, providing additional macro support for pharma names.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
On the pipeline front, Novo Nordisk is keeping its competitive edge sharp. The combination therapy CagriSema delivered a 20.2% weight loss over 68 weeks in a phase 3 trial, bolstering its case against Eli Lilly’s oral GLP-1 candidates. The FDA is currently reviewing CagriSema’s approval application, with a decision expected in the fourth quarter. Separately, the company is testing Cagrilintide as a weekly injection specifically for patients who discontinue existing GLP-1s due to nausea — a move that could expand the addressable market.
The stock is also getting support from a steady buyback program. Novo Nordisk has repurchased roughly 1% of its outstanding shares, tightening supply and providing a price floor. Even a mid-June data breach that exposed pseudonymised patient records has failed to derail sentiment. The company’s core operations remain unaffected, though a forensic investigation continues.
Chart technicians, however, warn of near-term caution. The relative strength index has climbed to 71.3, flashing overbought territory. While the stock has reclaimed its 200-day moving average near €41 and sits comfortably above the 50-day line, the RSI suggests a pullback could be imminent. On a year-to-date basis, shares still trail by about 5%.
The real test arrives on August 5, when Novo Nordisk reports second-quarter earnings. Investors will zero in on patient persistence rates for the Wegovy pill — high early prescriptions mean little if patients don’t titrate up to therapeutic doses. Only sustained adherence will convert script counts into durable revenue growth.
Ad
Novo Nordisk Stock: New Analysis - 27 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
